SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to…

SAB Biotherapeutics, Inc. · 8-K filed Jul 7, 2026 at 08:15 ET

At the news

BULLISHIMPACT 4/10

8-K filed Jul 7, 2026 at 08:15 ET

SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis. The investigator-led study extends the clinical program beyond the typical 100-day window and complements the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co-fund the study; the grant amount was not disclosed.

  • Breakthrough T1D awarded a grant to Dr. Michael Haller at University of Florida for the PRISE-hATG study of SAB-142.
  • PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis, extending beyond the typical 100-day window.
  • The study is randomized, double-blind, placebo-controlled and harmonized with the Phase 2b SAFEGUARD trial.
  • SAB BIO will co-fund the study; grant amount not disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access